Status:
COMPLETED
Mucosal Gene Expression Defects in IBD
Lead Sponsor:
KU Leuven
Collaborating Sponsors:
Fund for Scientific Research, Flanders, Belgium
Conditions:
Inflammatory Bowel Diseases
Eligibility:
All Genders
18+ years
Brief Summary
This study investigated the mucosal gene expression defects associated with active Crohn's disease (CD)and ulcerative colitis (UC), and studied the effect of infliximab induced downregulation of infla...
Detailed Description
Infliximab, a monoclonal IgG1 antibody to the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α), was the first efficacious biological therapy for IBD. Infliximab dramatically improved the ...
Eligibility Criteria
Inclusion
- Clinical diagnosis of inflammatory bowel disease (Crohn's disease or ulcerative colitis)
- Patients with inflammatory bowel disease refractory to corticosteroids and/or immunosuppression who had never been treated with biological therapy (anti-TNF treatment).
Exclusion
- \-
Key Trial Info
Start Date :
July 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT00639821
Start Date
July 1 2004
End Date
February 1 2008
Last Update
October 22 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Gastroenterology
Leuven, Belgium, 3000